Saudi Arabia’s SAJA Pharma bought a 51% stake in Egyptian pharma company Biopharm, according to Al Borsa. The acquisition, whose was not revealed, was followed by an additional EGP 132.6 mn by SAJA into the company. The move comes as part of a strategy to increase their presence in Egypt. Baker and Mckenzie was the legal advisor on the transaction.
More from Enterprise
How correspondent banking works, and what the FinCEN clampdown on Banque Misr UAE means for business
As FinCEN proposes cutting Banque Misr’s UAE branches from USD…
Inside the financing of Egypt’s IPP boom
The contracts and the resources are proven, so the open…
EGX30 gained 2.79% in 3Q, but September gave back most of its July-August run, with mid-caps falling the hardest
Small- and mid-cap indices widened their lead over the benchmark…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…